Literature DB >> 2790003

p-Nitrophenyl 3-diazopyruvate and diazopyruvamides, a new family of photoactivatable cross-linking bioprobes.

V S Goodfellow1, M Settineri, R G Lawton.   

Abstract

p-Nitrophenyl 3-diazopyruvate (DAPpNP) has been developed as a heterobifunctional cross-linking agent for synthesis of photoaffinity probes and photoactivatable cross-linking agents that are nucleophile specific. p-Nitrophenyl chloroglyoxylate is formed in high yield from oxalyl chloride and p-nitrophenol. Subsequent reaction with diazomethane produces DAPpNP in 50-60% overall yield. DAPpNP acylates primary and secondary amines to form 3-diazopyruvamides in high yields. 3-Diazopyruvamide derivatives have been formed from a wide variety of amines including aromatic amines, amino acids, and peptides. 3-Diazopyruvamides undergo photolysis and Wolff rearrangement at 300 nm to produce a ketene amide, which efficiently acylates nucleophilic species to form malonic acid amide derivatives. A family of photoactivatable 3-diazopyruvamide cross-linking agents was synthesized from amino acids. A cleavable, thiol-specific photoactivatable cross-linking agent was synthesized from cystamine. These reagents were caused to react with rabbit muscle aldolase to form mainly dimeric cross-linked species.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790003     DOI: 10.1021/bi00441a030

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  2 in total

1.  End-specific covalent photo-dependent immobilisation of synthetic DNA to paramagnetic beads.

Authors:  R Penchovsky; E Birch-Hirschfeld; J S McCaskill
Journal:  Nucleic Acids Res       Date:  2000-11-15       Impact factor: 16.971

2.  Collagen cross linking agents: design and development of a multifunctional cross linker.

Authors:  Richard S Givens; Abraham L Yousef; Shaorong Yang; George T Timberlake
Journal:  Photochem Photobiol       Date:  2008 Jan-Feb       Impact factor: 3.421

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.